BioNTech to Acquire CureVac in $1.25B Deal, Shareholders Weigh Offer
BioNTech is set to acquire biotech giant CureVac in a deal valued at $1.25 billion. Both companies' CEOs and supervisory boards have approved the merger, aiming to bundle their mRNA and cancer research technologies. However, the transaction hinges on at least 80% of CureVac shareholders tendering their shares, with investors currently weighing the offer of $5.46 per share in BioNTech stock.
CureVac shareholders are focused on the takeover price, with analysts seeing limited room for independent price negotiations. BioNTech's offer values CureVac at around $1.25 billion, with the deal expected to close by 2025, making CureVac a wholly-owned subsidiary. Both sides have agreed to drop all US patent proceedings by August 2025. BioNTech can lower the shareholder approval threshold to 75 percent under certain conditions, creating a pivotal decision for CureVac investors.
The future of both BioNTech and CureVac is set to merge, with the strategic goal of bundling their technologies and cancer research pipelines. However, the success of the deal relies on enough CureVac shareholders accepting the offer, with the final outcome expected by 2025.
Read also:
- Eric Dane Diagnosed with ALS, Advocates for ACT for ALS
- Deepwater Horizon Oil Spill: BP Faces Record-Breaking Settlement - Dubbed 'Largest Environmental Fine Ever Imposed'
- Meta Unveils Ray-Ban AR Display Sunglasses; TikTok Agrees to $200 Million Deal
- Washington Voters Decide on Historic Carbon Tax Initiative I-1631
